Big pharma is facing another round of major patent expirations. Before the decade's end, Bristol Myers Squibb (BMS) will lose exclusivity for the megablockbuster blood thinner Eliquis as well as its all-star cancer drug Opdivo.

Merck, for its part, is also poised to lose patent protection for its flagship cancer medication Keytruda before 2030. Several other high-value medications like 's Humira and BMS's Revlimid have already lost patent protection, and copycat drugs are weighing heavily on their sales.

Image source: Getty Images.

Continue reading

Source Fool.com